Selected article for: "antiviral agent and biological activity"
Author: Allawadhi, Prince; Singh, Vishakha; Khurana, Amit; Khurana, Isha; Allwadhi, Sachin; Kumar, Pawan; Banothu, Anil Kumar; Thalugula, Sunitha; Barani, Percy Jasmine; Naik, Ramavath Redya; Bharani, Kala Kumar
Title: Silver nanoparticle based multifunctional approach for combating COVID-19
  • Cord-id: 6vmajhhj
  • Document date: 2021_6_2
    • ID: 6vmajhhj
    Snippet: COVID-19 is a highly contagious and widespread disease that has strained the global healthcare system to the hilt. Silver nanoparticles (AgNPs) are well known for their potent antimicrobial, antiviral, immunomodulatory, and biosensing properties. AgNPs have been found to be potential antiviral agent that acts against many deadly viruses and is presumed to be effective against COVID-19. AgNPs can generate free radicals and reactive oxygen species (ROS) leading to apoptosis mediated cell death the
    Document: COVID-19 is a highly contagious and widespread disease that has strained the global healthcare system to the hilt. Silver nanoparticles (AgNPs) are well known for their potent antimicrobial, antiviral, immunomodulatory, and biosensing properties. AgNPs have been found to be potential antiviral agent that acts against many deadly viruses and is presumed to be effective against COVID-19. AgNPs can generate free radicals and reactive oxygen species (ROS) leading to apoptosis mediated cell death thereby inhibiting viral infection. The shape and size of AgNPs play an important role in its biomedical applications as alterations may result in variable biological interaction and activity. Herein, we propose that AgNPs can be utilized for the effective management of the ongoing COVID-19 pandemic by highlighting the current status of AgNPs in the fight against COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphocyte proliferation: 1, 2, 3
    • acute respiratory syndrome and macrophage exposure: 1, 2, 3
    • adjuvant therapy and lung inflammation: 1, 2, 3